{
    "clinical_study": {
        "@rank": "57291", 
        "arm_group": [
            {
                "arm_group_label": "EGFR vaccine with GMCSF", 
                "arm_group_type": "Experimental", 
                "description": "EGFR antisense DNA 500 mcg peptide w/GMCSF monthly x 6 m"
            }, 
            {
                "arm_group_label": "EGFR vaccine with KLH", 
                "arm_group_type": "Experimental", 
                "description": "EGFR antisense DNA 500 mcg peptide w/KLH monthly x 6 m"
            }
        ], 
        "brief_summary": {
            "textblock": "RATIONALE: Vaccines made from a peptide may make the body build an immune response to kill\n      cancer cells.\n\n      PURPOSE: This phase I trial is studying two different vaccines to treat patients who have\n      gastric, prostate, or ovarian cancer."
        }, 
        "brief_title": "S0114 Vaccine Therapy in Treating Patients With Gastric, Prostate, or Ovarian Cancer", 
        "completion_date": {
            "#text": "November 2008", 
            "@type": "Actual"
        }, 
        "condition": [
            "Brain Tumors", 
            "Gastric Cancer", 
            "Ovarian Cancer", 
            "Prostate Cancer"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Brain Neoplasms", 
                "Stomach Neoplasms", 
                "Ovarian Neoplasms", 
                "Prostatic Neoplasms"
            ]
        }, 
        "detailed_description": {
            "textblock": "OBJECTIVES:\n\n        -  Determine the toxicity of EGFRvIII peptide vaccine with sargramostim (GM-CSF) or\n           keyhole limpet hemocyanin (KLH) as adjuvant in patients with EGFRvIII-expressing\n           cancer.\n\n        -  Determine the preexisting antibody and T-cell responses to EGFRvIII in these patients.\n\n        -  Determine the antibody and T-cell responses to EGFRvIII peptide after immunization with\n           this vaccine with GM-CSF or KLH as adjuvant.\n\n      OUTLINE: Patients are assigned to one of two treatment arms.\n\n        -  Arm I: Patients receive a vaccine containing EGFRvIII peptide admixed with sargramostim\n           (GM-CSF) intradermally monthly.\n\n        -  Arm II: Patients receive a vaccine containing EGFRvIII peptide admixed with keyhole\n           limpet hemocyanin subcutaneously monthly.\n\n      Treatment in both arms continues for 6 months in the absence of disease progression or\n      unacceptable toxicity.\n\n      Patients are followed every 3 months for 1 year.\n\n      PROJECTED ACCRUAL: A total of 24 patients (12 per treatment arm) will be accrued for this\n      study."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "DISEASE CHARACTERISTICS:\n\n          -  Histologically confirmed diagnosis of one the following:\n\n               -  Stage II-IV gastric cancer\n\n               -  Stage IIC-IV ovarian cancer in first complete remission\n\n                    -  CA 125 normal and stable*\n\n               -  Grade III anaplastic astrocytoma\n\n               -  Stage IV (M1) prostate adenocarcinoma\n\n                    -  No small cell variations\n\n                    -  No biochemical progression after definitive surgery, defined by the\n                       following:\n\n                         -  Prostate-specific antigen more than 0.4 ng/mL which remains elevated\n                            on 2 additional measurements at least 2 weeks apart after\n                            prostatectomy\n\n                         -  Three consecutive rises in PSA, each at least 1 month apart after\n                            definitive radiotherapy\n\n                    -  Must be receiving androgen blockade\n\n                    -  PSA less than 5 ng/mL and stable*\n\n          -  Documented EGFRvIII expression in primary tumor\n\n          -  Must have received prior surgery and or chemoradiotherapy for disease (except\n             prostate cancer patients) NOTE: *Stable defined as no increase over 2 measurements at\n             least 28 days apart with the last measurement within the past 28 days\n\n        PATIENT CHARACTERISTICS:\n\n        Age:\n\n          -  80 and under\n\n        Performance status:\n\n          -  Zubrod 0\n\n        Life expectancy:\n\n          -  Not specified\n\n        Hematopoietic:\n\n          -  WBC at least 3,000/mm^3\n\n          -  Platelet count at least 100,000/mm^3\n\n          -  Hemoglobin at least 10 g/dL\n\n        Hepatic:\n\n          -  SGOT no greater than 2.5 times upper limit of normal (ULN)\n\n          -  Alkaline phosphatase no greater than 2.5 times ULN\n\n          -  No hepatitis\n\n        Renal:\n\n          -  Not specified\n\n        Other:\n\n          -  No other malignancy in the past 5 years except adequately treated basal cell or\n             squamous cell skin cancer, carcinoma in situ of the cervix, or adequately treated\n             stage I or II cancer in complete remission\n\n          -  No contraindication to receiving sargramostim (GM-CSF) or KLH-based vaccine products\n\n          -  No autoimmune disease\n\n          -  HIV negative\n\n          -  Not pregnant or nursing\n\n          -  Negative pregnancy test\n\n          -  Fertile patients must use effective contraception\n\n        PRIOR CONCURRENT THERAPY:\n\n        Biologic therapy:\n\n          -  Not specified\n\n        Chemotherapy:\n\n          -  See Disease Characteristics\n\n          -  At least 1 month since prior cytotoxic chemotherapy\n\n          -  No concurrent chemotherapy\n\n        Endocrine therapy:\n\n          -  See Disease Characteristics\n\n          -  At least 1 month since prior treatment dose corticosteroids\n\n          -  No concurrent corticosteroids\n\n        Radiotherapy:\n\n          -  See Disease Characteristics\n\n          -  No concurrent radiotherapy\n\n        Surgery:\n\n          -  See Disease Characteristics\n\n        Other:\n\n          -  Recovered from all prior therapies\n\n          -  No concurrent enrollment on other phase I studies\n\n          -  No other concurrent immune modulators"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "80 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "14", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "September 13, 2001", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00023634", 
            "org_study_id": "CDR0000068824", 
            "secondary_id": [
                "U10CA032102", 
                "R01CA082661", 
                "S0114", 
                "UW-106"
            ]
        }, 
        "intervention": [
            {
                "arm_group_label": "EGFR vaccine with KLH", 
                "description": "100 mcg w/EGFRvIII", 
                "intervention_name": "KLH", 
                "intervention_type": "Biological", 
                "other_name": "keyhole limpet"
            }, 
            {
                "arm_group_label": "EGFR vaccine with GMCSF", 
                "description": "arm 1: 100 mcg w/EGFRvIII", 
                "intervention_name": "GMCSF", 
                "intervention_type": "Biological", 
                "other_name": "sargramostim"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "stage II gastric cancer", 
            "stage III gastric cancer", 
            "stage IV gastric cancer", 
            "recurrent gastric cancer", 
            "adenocarcinoma of the prostate", 
            "stage II ovarian epithelial cancer", 
            "stage III ovarian epithelial cancer", 
            "stage IV ovarian epithelial cancer", 
            "recurrent adult brain tumor", 
            "stage IV prostate cancer", 
            "recurrent prostate cancer", 
            "adult anaplastic astrocytoma"
        ], 
        "lastchanged_date": "July 20, 2012", 
        "link": {
            "description": "Clinical trial summary from the National Cancer Institute's PDQ\u00ae database", 
            "url": "http://cancer.gov/clinicaltrials/SWOG-S0114"
        }, 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Bay City", 
                        "country": "United States", 
                        "state": "Michigan", 
                        "zip": "48708"
                    }, 
                    "name": "Bay Regional Medical Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Port Huron", 
                        "country": "United States", 
                        "state": "Michigan", 
                        "zip": "48060"
                    }, 
                    "name": "Mercy Regional Cancer Center at Mercy Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bellingham", 
                        "country": "United States", 
                        "state": "Washington", 
                        "zip": "98225"
                    }, 
                    "name": "St. Joseph Hospital Community Cancer Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bremerton", 
                        "country": "United States", 
                        "state": "Washington", 
                        "zip": "98310"
                    }, 
                    "name": "Olympic Hematology and Oncology"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Mt. Vernon", 
                        "country": "United States", 
                        "state": "Washington", 
                        "zip": "98273"
                    }, 
                    "name": "Skagit Valley Hospital Cancer Care Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Seattle", 
                        "country": "United States", 
                        "state": "Washington", 
                        "zip": "98195-6043"
                    }, 
                    "name": "University Cancer Center at University of Washington Medical Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Seattle", 
                        "country": "United States", 
                        "state": "Washington", 
                        "zip": "98114"
                    }, 
                    "name": "Swedish Cancer Institute at Swedish Medical Center - First Hill Campus"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Seattle", 
                        "country": "United States", 
                        "state": "Washington", 
                        "zip": "98104"
                    }, 
                    "name": "Fred Hutchinson Cancer Research Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Seattle", 
                        "country": "United States", 
                        "state": "Washington", 
                        "zip": "98112"
                    }, 
                    "name": "Group Health Central Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Seattle", 
                        "country": "United States", 
                        "state": "Washington", 
                        "zip": "98104"
                    }, 
                    "name": "Harborview Medical Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Sedro-Wooley", 
                        "country": "United States", 
                        "state": "Washington", 
                        "zip": "98284"
                    }, 
                    "name": "North Puget Oncology at United General Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Spokane", 
                        "country": "United States", 
                        "state": "Washington", 
                        "zip": "99202"
                    }, 
                    "name": "Cancer Care Northwest - Spokane South"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Wenatchee", 
                        "country": "United States", 
                        "state": "Washington", 
                        "zip": "98801"
                    }, 
                    "name": "Wenatchee Valley Clinic"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "An Early Phase Study of an EGFRvIII Peptide Based Vaccine in Patients With EGFRvIII Expressing Cancers", 
        "overall_official": {
            "affiliation": "Department of Veterans Affairs", 
            "last_name": "Robert B. Montgomery, MD", 
            "role": "Study Chair"
        }, 
        "overall_status": "Terminated", 
        "oversight_info": {
            "authority": "United States: Federal Government", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "November 2008", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "toxicity", 
            "safety_issue": "Yes", 
            "time_frame": "during treatment"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00023634"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Southwest Oncology Group", 
        "sponsors": {
            "collaborator": {
                "agency": "National Cancer Institute (NCI)", 
                "agency_class": "NIH"
            }, 
            "lead_sponsor": {
                "agency": "Southwest Oncology Group", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "June 2001", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "July 2012", 
        "why_stopped": "lack of accrual"
    }, 
    "geocoordinates": {
        "Bay Regional Medical Center": "43.594 -83.889", 
        "Cancer Care Northwest - Spokane South": "47.659 -117.426", 
        "Fred Hutchinson Cancer Research Center": "47.606 -122.332", 
        "Group Health Central Hospital": "47.606 -122.332", 
        "Harborview Medical Center": "47.606 -122.332", 
        "Mercy Regional Cancer Center at Mercy Hospital": "42.971 -82.425", 
        "North Puget Oncology at United General Hospital": "48.504 -122.236", 
        "Olympic Hematology and Oncology": "47.57 -122.653", 
        "Skagit Valley Hospital Cancer Care Center": "48.421 -122.334", 
        "St. Joseph Hospital Community Cancer Center": "48.76 -122.488", 
        "Swedish Cancer Institute at Swedish Medical Center - First Hill Campus": "47.606 -122.332", 
        "University Cancer Center at University of Washington Medical Center": "47.606 -122.332", 
        "Wenatchee Valley Clinic": "47.423 -120.31"
    }
}